Exchange: NASDAQ·Updated 10:38 AM EDT

RNTX News

News
all
press releases
Here's Why You Should Add RNTX Stock to Your Portfolio Now
Rein Therapeutics advances LTI-03 in IPF. RENEW enrollment tops 25%, with interim data expected in the fourth quarter of 2026.
Zacks
All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy
Rein Therapeutics Inc. (RNTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Rein Therapeutics Inc. (NASDAQ:RNTX) Short Interest Down 51.4% in April
Rein Therapeutics Inc. (NASDAQ:RNTX - Get Free Report) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 236,711...
MarketBeat

Advertisement|Remove ads.